A: Determination of the expression of TCF3 and miR-101 in Burkitt lymphoma (BL) tissues and lymph node reactive hyperplasia tissues (RLNH) using qRT-PCR, **p < 0.01 vs. RLNH group; B: Determination of the TCF3 expression in the lymphoma cell lines (Namalwa, Raji, Daudi) and lymphocytes (OCI-LY1) using qRT-PCR; C: Determination of the expression of miR-101 using qRT-PCR; D: Evaluation of the expression of TCF3 protein using Western blot; E: Protein quantitative grayscale statistics, **p < 0.01 vs. OCI-LY1 group. This evidence concerns the gene TCF3 and Burkitt lymphoma.